{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Clark J"],"funding":["NCATS NIH HHS","NIAID NIH HHS","NCI NIH HHS","NIH HHS","NIGMS NIH HHS"],"pubmed_abstract":["Neutralizing antibodies correlate with protection against SARS-CoV-2. Recent studies, however, show that binding antibody titers, in the absence of robust neutralizing activity, also correlate with protection from disease progression. Non-neutralizing antibodies cannot directly protect from infection but may recruit effector cells thus contribute to the clearance of infected cells. Also, they often bind conserved epitopes across multiple variants. We characterized 42 human mAbs from COVID-19 vaccinated individuals. Most of these antibodies exhibited no neutralizing activity <i>in vitro</i> but several non-neutralizing antibodies protected against lethal challenge with SARS-CoV-2 in different animal models. A subset of those mAbs showed a clear dependence on Fc-mediated effector functions. We determined the structures of three non-neutralizing antibodies with two targeting the RBD, and one that targeting the SD1 region. Our data confirms the real-world observation in humans that non-neutralizing antibodies to SARS-CoV-2 can be protective."],"journal":["bioRxiv : the preprint server for biology"],"pagination":["2024.02.28.582613"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10925278"],"repository":["biostudies-literature"],"pubmed_title":["Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination."],"pmcid":["PMC10925278"],"funding_grant_id":["75N93021C00014","75N93019C00051","U19 AI168631","S10 OD030463","S10 OD026880","UL1 TR004419","U24 GM129539","75N91019D00024","R01 AI168178","P01 AI172531"],"pubmed_authors":["Hoxie I","Clark J","Raskin A","Bajic G","Ellebedy AH","Amanat F","Simon V","Yong JS","Sun W","Edgar JE","Bournazos S","Singh G","Krammer F","Gonzalez-Dominguez I","Carreno JM","Sapse IA","Tcheou J","Adelsberg DC","Andreata-Santos R"],"additional_accession":[]},"is_claimable":false,"name":"Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.","description":"Neutralizing antibodies correlate with protection against SARS-CoV-2. Recent studies, however, show that binding antibody titers, in the absence of robust neutralizing activity, also correlate with protection from disease progression. Non-neutralizing antibodies cannot directly protect from infection but may recruit effector cells thus contribute to the clearance of infected cells. Also, they often bind conserved epitopes across multiple variants. We characterized 42 human mAbs from COVID-19 vaccinated individuals. Most of these antibodies exhibited no neutralizing activity <i>in vitro</i> but several non-neutralizing antibodies protected against lethal challenge with SARS-CoV-2 in different animal models. A subset of those mAbs showed a clear dependence on Fc-mediated effector functions. We determined the structures of three non-neutralizing antibodies with two targeting the RBD, and one that targeting the SD1 region. Our data confirms the real-world observation in humans that non-neutralizing antibodies to SARS-CoV-2 can be protective.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-05-25T03:08:44.493Z","creation":"2025-04-19T22:01:26.493Z"},"accession":"S-EPMC10925278","cross_references":{"pubmed":["38464151"],"doi":["10.1101/2024.02.28.582613"]}}